Monocyte chemoattractant protein-1 serum levels in patients with breast cancer.
The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425) pg/ml, respectively. No differences were ascertained between the patient groups. In patients with breast cancer, increased MCP-1 serum levels were correlated with advanced tumor stage (p = 0.04) and lymph node involvement (p = 0.04). We were not able to establish MCP-1 as a differentiation marker between malignant and benign breast diseases. Our data might indicate that MCP-1 influences breast carcinogenesis by facilitating tumor growth and metastatic spread, thus altering the biological phenotype of the disease.
Lebrecht
Antje
A
Department of Obstetrics and Gynecology, Johannes Gutenberg University Mainz, Mainz, Germany. lebrecht@klinik.uni-mainz.de
Grimm
Christoph
C
Lantzsch
Tilmann
T
Ludwig
Elisabeth
E
Hefler
Lukas
L
Ulbrich
Eva
E
Koelbl
Heinz
H
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D001941:Breast Diseases / Q000473:pathology*; D001943:Breast Neoplasms / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000473:pathology*; D016022:Case-Control Studies; D002471:Cell Transformation, Neoplastic; D018932:Chemokine CCL2 / Q000097:blood*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D010641:Phenotype; D012016:Reference Values; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; D018932:Chemokine CCL2